GCM
ANIK icon

Gladius Capital Management’s Anika Therapeutics ANIK Stock Holding History

Gladius Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,601
Closed -$39K – 354
2022
Q3 		$39K Buy
+1,601
New +$36.8K ﹤0.01% 225

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Gladius Capital Management's ANIK Position: Q4 2022 in Review

Gladius Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2022, closing a stake of 1,601 shares — an estimated $39K sold.

Gladius Capital Management first reported a position in ANIK in Q3 2022 and held it in 1 quarter. The position peaked at $39K in Q3 2022. 123 funds tracked by Wall St. Rank hold ANIK as of Q4 2022.

  • Gladius Capital Management reported no remaining Anika Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gladius Capital Management sold 1,601 Anika Therapeutics shares in Q4 2022, an estimated $39K.
  • Gladius Capital Management first reported a position in Anika Therapeutics in Q3 2022 and held it in 1 quarter.
  • Gladius Capital Management's Anika Therapeutics position peaked at $39K in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2022.

Based on Gladius Capital Management's 13F filing for Q4 2022, filed 2 Feb 2023.